NCT06252753Recruiting
Observational Study Protocol: LIVER-R
An Observational Multi-Center Study to Evaluate Real-World Treatment Outcomes With or Without Durvalumab-Based Regimens in Hepatobiliary Cancers
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multi-country, multi-center, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with or without a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of regimens (durvalumab-based or otherwise) in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, treatment provider characteristics, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, time to treatment discontinuation, recurrence-free survival, and time to treatment recurrence ).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 21 Dec 2023
- Start date
- 20 Dec 2023
- Primary completion date
- 30 Dec 2030
- Lead sponsor
- AstraZeneca
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06252753
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 20 Dec 2023 to the primary completion date, 30 Dec 2030
- 146 sites in 22 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Second primary malignancy prior to HCC or BTC diagnosis
- aBTC Specific Exclusion Criteria
- A patient will be excluded from participating in the aBTC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:
- Received a liver transplant during the baseline period
- Received more than 1 cycle of Gemcitabine + Cisplatin for biliary tract cancer on or after diagnosis of unresectable, locally advanced or metastatic disease through the index date. Patients who received any systemic therapy while having early stage, resectable disease are eligible
- uHCC Specific Exclusion Criteria
- A patient will be excluded from participating in the uHCC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:
- Received a liver transplant during the baseline period
- Received other systemic therapies for hepatobiliary cancer indication on or after diagnosis date through the index date
- eeHCC Specific Exclusion Criteria
- A patient will be excluded from participating in the eeHCC cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:
- Eligible for curative therapy at the time of receiving LRT (ablation)
- Receipt of systemic therapy prior to index LRT in the baseline period
- Liver transplant any time prior to index
- EMERALD Specific Exclusion Criteria
- A patient will be excluded from participating in the EMERALD cohort if they meet any of the general exclusion criteria 1-2 or any of the following criteria:
- Eligible for curative therapy at the time of receiving LRT (ablation)
- Receipt of systemic therapy prior to index LRT in the baseline period
- Liver transplant any time prior to index
Other illness
- Currently/was participating or plans to participate in any clinical trial for investigational treatment for hepatobiliary cancers on or after the diagnosis date until the index date
- Portal vein tumor thrombosis (PVTT) of VP3/4
- Portal vein tumor thrombosis (PVTT) of VP3/4
Other
- General Exclusion Criteria
- A patient will be excluded from participating in this study if they meet any of the following general criteria 1-2 or any cohort specific exclusion criteria:
- Extrahepatic spread
- Extrahepatic spread
Who the study is looking for
- All patients must meet all of the following general criteria 1-4 along with all respective cohort specific criteria noted below:
- Age ≥18 years and a lawful adult in the country at the index date
- Confirmed presence of malignancy of primary hepatobiliary cancer by any method (e.g., radiological, histological, etc.)
- Decision to treat was made independently and prior to obtaining informed consent
- Informed consent was obtained as per country level regulations (includes waiver of consent for retrospective data collection if approved)
- aBTC Specific Inclusion Criteria
- A patient will be eligible to be included in the aBTC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:
- Patient has unresectable aBTC
- Has received or is intending to receive a durvalumab-based regimen (may have been treated in an EAP)
- uHCC Specific Inclusion Criteria
- A patient will be eligible to be included in the uHCC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:
- Patient has unresectable uHCC
- Not eligible for LRT, as well as for those who progressed following LRT
- Has received or is intending to receive a durvalumab-based regimen (may have been treated in an EAP)
- eeHCC Specific Inclusion Criteria
- A patient will be eligible to be included in the eeHCC cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:
- HCC confirmed by radiological or histological diagnosis
- Child-Pugh A-B7
- Disease not amenable to curative treatment but amenable to LRT at index
- Patients with liver-confined HCC who initiated first non-curative intent LRT on or after 01 January 2024
- Patients eligible for LRT with palliative intent such as TACE/ TARE/transarterial infusion chemotherapy (TAIC)/ hepatic arterial infusion chemotherapy (HAIC)/transarterial embolization (TAE) given by itself or in combination with other systemic therapy (can include durvalumab) within 60 days of the LRT
- EMERALD Specific Inclusion Criteria
- A patient will be eligible to be included in the EMERALD cohort if they meet all general inclusion criteria 1-4 in addition to the following criteria:
- HCC confirmed by radiological or histological diagnosis
- Child-Pugh score of A-B7
- Liver-confined disease not amenable to curative treatment but amenable to LRT at index
- Receipt of a durvalumab-based regimen in combination with LRT administered within 28 days of each other (index is the first of the two treatments administered)
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (146)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.Future Oncol · 2025 · PMID 41277677
This page is information, not medical advice. Discuss any trial with your doctor.